Last reviewed · How we verify

NCT04733911

Recovery Kinetics Following Eccentric Exercise

Completed NA Last updated 10 June 2022
What this trial tests

NA trial testing 75 eccentric contractions in Muscle Damage in 10 participants. Completed in 30 April 2022.

Timeline
1 April 2021
Primary endpoint
28 February 2022
30 April 2022

Quick facts

Lead sponsorUniversity of Thessaly
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposebasic science
Enrollment10
Start date1 April 2021
Primary completion28 February 2022
Estimated completion30 April 2022
Sites1 location across Greece

Drugs / interventions tested

Conditions studied

Sponsor

University of Thessaly

Who can join

Adults 18 to 30, male only, with Muscle Damage. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study will be to investigate the recovery kinetics of neuromuscular fatigue, muscle microtrauma indicators, performance and oxidative stress factors after three different exercise induced muscle damage (EIMD) protocols in adult Males. Also, this study will determine the comparison among three different eccentric protocols in neuromuscular fatigue, muscle microtrauma indicators, performance and oxidative stress factors. The eccentric protocols will be differentiated in training volume and specifically in the eccentric repetitions in isokinetic dynamometer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Muscle Damage

Currently open trials in the same condition.

Other University of Thessaly trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04733911.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing